Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

Peng, Yulin; Wang, Yan; Tang, Ning; Sun, Dongdong; Lan, Yu‐Long; Yu, Zhenlong; Zhao, Xinyu; Feng, Lei; Zhang, Baojing; Jin, Lingling; Yu, Fabiao; Ma, Xiaochi; Lv, Chuanzhu

doi:10.1186/s13046-018-0926-9

Public

Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

Published in Journal of Experimental & Clinical Cancer Research • Oct 12, 2018

Authors:

Yulin Peng

Yan Wang

Ning Tang

Abstract

BACKGROUND: Andrographolide (Andro), a diterpenoid lactone, has been used for treatment of various cancers with less adverse effects. However, the underlying mechanisms regarding its anti-tumor mechanism still remain unclear. METHODS: Cell viability and proliferation were measured by CCK8 and CFSE d...

Subject

Andrographolide

Angiogenesis

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!